- Roger W. Sommi, PharmD, FCCP, BCPP, has affiliations with Otsuka, Merck, Sunovion, and Takeda (Speaker's Bureau); Otsuka, Janssen, and NIH (Research).
- Dawn I. Velligan, MD, has affiliations with Genentech, Amgen, Abbvie, Otsuka, Lundbeck, and Janssen (Advisory); Genentech and Amgen (Research).
- Peter J. Weiden, MD, has affiliations with Delpor, Johnson & Johnson (Janssen), Genentech, Roche, Lundbeck, Otsuka, Novartis, Reckitt Benckiser Pharmaceuticals, and Sunovion (Consulting); Johnson & Johnson (Janssen), Genentech, Roche, Lundbeck, Otsuka, Novartis, and Sunovion (Speaker's Bureau); Johnson & Johnson (Janssen), Genentech, Roche, Neurocrine, Novartis, and Sunovion (Research).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CPE activity:
- Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
- Cynthia M. Kunzer, CMP, has no affiliations with commercial interests to disclose.
The College of Psychiatric and Neurologic Pharmacists
- Mary C. Borovicka, PharmD, BCPS, BCPP, has no affiliations with commercial interests to disclose.
- Brenda Schimenti, MS, has no affiliations with commercial interests to disclose.
DISCLOSURE OF UNLABELED USE AND DISCLAIMER:
This educational activity does not contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA).
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of RMEI, CPNP, Otsuka and Lundbeck. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease. CONTINUING PHARMACY EDUCATION
The College of Psychiatric and Neurologic Pharmacists (CPNP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
COURSE VIEWING REQUIREMENTS
Credits: 1.0 Contact Hour of ACPE Credit
Type of Activity: Application
Estimated time to complete: 60 minutes
There is no fee for this educational activity. COMMERCIAL SUPPORT
This activity is jointly sponsored by RMEI, LLC and The College of Psychiatric and Neurologic Pharmacists. RMEI gratefully acknowledges an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck in support of this CPE activity. HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, pharmacists are entitled to receive 1.0 Contact Hour of ACPE Credit. A transcript of credit will be available to print from your user history page with reporting to CPE Monitor to occur within one business day.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Pharmacists who successfully complete the post-test and evaluation will receive CPE credit. You must score with a 70% or higher on the post-test to receive credit for this activity. You will have two attempts to take the post-test.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above
For video playback, install the latest version of Flash or Quicktime.